Mar 14, 2016
The Conquer Cancer Foundation of ASCO is pleased to announce the recipients of its 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancer, Genitourinary Cancer, Cancer Survivorship, and Quality Care. The following 74 young investigators, recognized for the scientific merit of their abstracts and their valuable contributions to their areas of study, accepted their awards and presented their research findings at recent thematic symposia.
2016 Conquer Cancer Foundation of ASCO Merit Awards in Genitourinary Cancers
Twenty-six Merit Award recipients were recognized at the 2016 Genitourinary Cancers Symposium, which took place January 7-9 in San Francisco, CA. The recipients and their abstracts are:
- Nabil Adra, MD, Indiana University Melvin and Bren Simon Cancer Center
Survival outcomes of patients with metastatic germ cell tumor (mGCT) treated from 1998 to 2012: The Indiana University (IU) experience. (Abstract 491) - Christopher Brian Allard, MD, FRCSC, Harvard Medical School
Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study. (Abstract 306) - Aditya Bagrodia, MD, Memorial Sloan Kettering Cancer Center
Actionable targets in patients with cisplatin-resistant advanced germ cell tumors. (Abstract 473) - Paulo Gustavo Bergerot, Federal University of São Paulo
Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies. (Abstract 363) - Brandon David Bernard, MD, Dana-Farber Cancer Institute
Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT). (Abstract 485) - Rohit Bose, MD, PhD, Memorial Sloan Kettering Cancer Center
Investigation of a frequently mutated transcriptional repressor in prostate cancer, in particular its role in modulating androgen signaling and its effects on TMPRSS2-ERG dependent tumor maintenance. (Abstract 274) - Bishoy Faltas, MD, Weill Cornell Medical College
Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing. (Abstract 354) - Mohammed Haseebuddin, MD, Fox Chase Cancer Center
PD-1 expression on classical monocytes (CM) as an independent predictor of cancer specific survival in clear cell renal carcinoma (ccRCC). (Abstract 562) - Naresh Jegadeesh, MD, Winship Cancer Institute of Emory University
The role of adjuvant radiotherapy in pathologically node positive prostate cancer. (Abstract 28) - Louis Spencer Krane, MD, National Cancer Institute
High throughput screening to assess urothelial cancer lines and their metastatic derivatives for assessing changes in sensitivity in therapeutics. (Abstract 407) - Michael S. Leapman, MD, University of California, San Francisco
Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. (Abstract 76) - Jeremy Howard Lewin, MBBS, FRACP, Princess Margaret Cancer Centre, University Health Network
Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT). (Abstract 493) - Ankit Madan, MD, MBBS, University of Alabama
The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC). (Abstract 215) - Stephen A. Mihalcik, MD, PhD, Harvard Radiation Oncology Program
Comorbidity and the receipt of curative therapy for favorable-risk prostate cancer prior to and following the publication of PIVOT. (Abstract 17) - Raphael Brandao Moreira, MD, Antonio Ermirio de Moraes Oncology Center
Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials. (Abstract 73) - Matthew Mossanen, MD, University of Washington School of Medicine
Comparative effectiveness of a patient centered pathology report for bladder cancer care. (Abstract 420) - Jure Murgic, MD, Princess Margaret Hospital/University Health Network, University of Toronto
Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy. (Abstract 101) - Eric Ojerholm, MD, University of Pennsylvania
Neutrophil-to-lymphocyte ratio as a prognostic biomarker in bladder cancer: A REMARK-guided secondary analysis of SWOG 8710. (Abstract 361) - Moshe Chaim Ornstein, MD, MA, Cleveland Clinic, Taussig Cancer Institute
Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC). (Abstract 434) - Jorge Ramos, DO, Fred Hutchinson Cancer Research Center
Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT). (Abstract 422) - Tracy Lynn Rose, MD, MPH, The University of North Carolina at Chapel Hill
Genomic differences and survival in African Americans with metastatic clear cell renal cell carcinoma in the targeted therapy era. (Abstract 504) - Jose Manuel Ruiz Morales, MD, Tom Baker Cancer Centre, University of Calgary
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (Abstract 544) - Divya Sahu, PhD, University of California, San Diego
Metabolomics analysis of non-muscle invasive and muscle-invasive bladder cancer. (Abstract 362) - Konrad Hermann Stopsack, MD, MPH, Mayo Clinic
Increased cholesterol synthesis via squalene monooxygenase to predict lethal prostate cancer. (Abstract 77) - Debasish Sundi, MD, The University of Texas MD Anderson Cancer Center
Differential expression of FOXF1 in bladder cancer metastases and association with established bladder cancer subtypes. (Abstract 464) - Ilya Tsimafeyeu, MD, Kidney Cancer Research Bureau
FGFR2 expression to predict survival outcome in patients with metastatic papillary renal cell carcinoma. (Abstract 506)
The 2016 Conquer Cancer Foundation of ASCO Merit Awards in Genitourinary Cancers are supported by Amgen; AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Janssen Oncology; Lilly; Spectrum Pharmaceuticals; and Takeda Oncology.
2016 Conquer Cancer Foundation of ASCO Merit Awards in Cancer Survivorship
Eight Merit Award recipients were recognized at the 2016 Cancer Survivorship Symposium, which took place January 15-16 in San Francisco, CA. The recipients and their abstracts are:
- Mohammad Issam Abu Zaid, MBBS, Indiana University School of Medicine
Cardiovascular disease (CVD) risk factors and health behaviors following cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS). (Abstract 129) - Lawson Eng, MD, Princess Margaret Cancer Centre
Elimination of second-hand smoke (SHS) exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient smoking cessation. (Abstract 183) - Douglas Beaty Fair, MD, Huntsman Cancer Institute
Impact of health care costs on utilization of needed health care in the Childhood Cancer Survivor Study (CCSS). (Abstract 20) - Dina M. Flink, MS, PhD(c), University of Colorado Denver
Fertility Attitudes and Cancer Treatment Study (FACTS). (Abstract 112) - Katie Greenzang, MD, EdM, Dana-Farber Cancer Institute
Parental preparedness for late effects in survivors of childhood cancer. (Abstract 85) - Derick Okwan-Duodu, MD, PhD, Winship Cancer Institute of Emory University
Progesterone to improve neurocognitive outcomes following cranial irradiation. (Abstract 128) - Ying Wang, MD, University of British Columbia
Young cancer survivors’ expectations of physicians for issues of mental health, interpersonal relationships, and reintegration to society. (Abstract 208) - AnnaLynn Williams, MS, University of Rochester School of Medicine and Dentistry
Cognitive function in cancer survivors: Analysis of the 1999-2002 National Health and Nutrition Examination Survey. (Abstract 193)
The 2016 Conquer Cancer Foundation of ASCO Merit Awards in Cancer Survivorship are supported by Amgen; AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Janssen Oncology; Lilly; Spectrum Pharmaceuticals; and Takeda Oncology.
2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancers
Twenty-five Merit Award recipients were recognized at the 2016 Gastrointestinal Cancers Symposium, which took place January 21-23 in San Francisco, CA. The recipients and their abstracts are:
- Kamran A. Ahmed, MD, Moffitt Cancer Center
Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT. (Abstract 239) - Daniel H. Ahn, DO, The Ohio State University Comprehensive Cancer Center
Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC). (Abstract 287) - Aisling S. Barry, MB, BCH, BAO, MRCPI, FFRRCSI, Princess Margaret Cancer Centre
The use of stereotactic body radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. (Abstract 418) - Nicholas Gerard Berger, MD, Medical College of Wisconsin
Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers. (Abstract 339) - Mohamed Bouattour, MD, Beaujon University Hospital
BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC. (Abstract 252) - May Thet Cho, MD, Barnes Jewish Hospital
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer. (Abstract 679) - Aileen Deng, MD, Thomas Jefferson University Hospital
Assessing solid tumor response with and without RECIST. (Abstract 504) - Cecilia Grace Ethun, MD, Winship Cancer Institute of Emory University
A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. (Abstract 202) - Luca Faloppi, MD, A.O.U. United Hospital
Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α—Final results of the ALICE-2 study. (Abstract 280) - Karuna Ganesh, MD, PhD, Memorial Sloan Kettering Cancer Center
Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC). (Abstract 564) - Evan Scott Glazer, MD, PhD, Moffitt Cancer Center
Association of decreased peak SUV on PET after neoadjuvant therapy in patients with borderline resectable pancreatic carcinoma with pathologic response. (Abstract 423) - Erin Greenleaf, MD, Penn State Milton S. Hershey Medical Center
Response to neoadjuvant chemotherapy and impact on survival for resected gastric cancer. (Abstract 122) - Arielle L. Heeke, MD, Georgetown University
Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome. (Abstract 505) - Bradley Krasnick, MD, Washington University School of Medicine in St. Louis
Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. (Abstract 388) - Richard M. Lee-Ying, MD, University of Calgary Tom Baker Cancer Centre
Outcomes of perioperative systemic therapy (ST) in patients with R0 resection of metastatic colorectal cancer (mCRC). (Abstract 496) - Katelin Anne Mirkin, MD, Penn State Milton S. Hershey Medical Center
Survival impact of neoadjuvant therapy in resected pancreatic cancer. (Abstract 367) - Chan-Young Ock, MD, Seoul National University Hospital
Effect of combined consideration of distinct signatures of VEGF and soluble VEGFR2 on prognostic implication in gastric cancer. (Abstract 56) - Sonia Tewani Orcutt, MD, Moffitt Cancer Center
Noninvasive markers to predict malignant intraductal papillary mucinous neoplasms of the pancreas. (Abstract 204) - Shinoj Pattali Jayavalsan, MD, Medical College of Wisconsin
Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? (Abstract 443) - Lauren McLendon Postlewait, MD, Winship Cancer Institute of Emory University
A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma. (Abstract 231) - Nitya Prabhakar Raj, MD, Memorial Sloan Kettering Cancer Center
Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT. (Abstract 246) - Elizabeth Catherine Smyth, The Royal Marsden Hospital
Phase II study of AZD4547 in FGFR amplified tumors: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. (Abstract 154) - Shelly Sud, MD, University of Ottawa
Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17. (Abstract 256) - Zhifei Sun, MD, Duke University Medical Center
Effect of combined neoadjuvant chemoradiation on overall survival for patients with locally advanced rectal cancer. (Abstract 657) - Sean Szeja, MD, The University of Texas Medical Branch, Galveston
Impact of radiation and surgery for intraductal papillary neoplasm of the bile duct: A population-based analysis. (Abstract 363)
The 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancers are supported by Amgen; AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Janssen Oncology; Lilly; Spectrum Pharmaceuticals; and Takeda Oncology.
2016 Conquer Cancer Foundation of ASCO Merit Awards in Quality Care
Fifteen Merit Award recipients were recognized at the 2016 Quality Care Symposium, which took place February 26-27 in Phoenix, AZ. The recipients and their abstracts are:
- Srinivas Banala, MD, The University of Texas MD Anderson Cancer Center
Safer transitions of care at a major cancer center: The emergency center to hospitalist experience. (Abstract 247) - Robert Michael Daly, University of Chicago Medical Center
Identifying avoidable terminal oncology ICU hospitalizations. (Abstract 56) - Wilfred P. Delacruz, San Antonio Military Medical Center
A quality improvement project to increase compliance with indicated prechemotherapy pneumococcal vaccination. (Abstract 218) - Tejas Desai, MSc, University of Toronto
Standardization of oral chemotherapy delivery to improve patient safety: A pilot study. (Abstract 90) - Julie Dunderdale, MD, Northwestern Memorial Hospital
The effect of obesity on operating room (OR) utilization in breast surgery. (Abstract 36) - Oluwadamilola M. Fayanju, MD, MA, MPHS, The University of Texas MD Anderson Cancer Center
Implementing value-based cancer care: A multidisciplinary approach to defining breast cancer outcomes. (Abstract 16) - Chunzi Jenny Jin, MD, Queen's University Cancer Research Institute
Quality of radiation therapy referral and utilization post-prostatectomy: A population-based study of time trends. (Abstract 286) - Ines B. Menjak, MD, FRCPC, University of Toronto
Successful completion of EGFR/ALK testing in non-squamous non-small cell lung cancer (non-sq NSCLC) with the implementation of reflex testing (RT) by pathologists. (Abstract 93) - Manali I. Patel, MD, MPH, Stanford University School of Medicine
Achieving the triple aim in cancer care through a tri-part research collaboration. (Abstract 52) - Ellie Proussaloglou, BS, University of Chicago Pritzker School of Medicine
Preferred cost communicator and financial distress (FD) in patients with cancer. (Abstract 26) - Mina Samir Sedrak, MD, University of Pennsylvania
Cancer communication in the social media age: Could Twitter help clinical trial accrual? (Abstract 194) - Meghan Shea, MD, Beth Israel Deaconess Medical Center
Integrating nursing into oral chemotherapy education. (Abstract 81) - Angela M. Stover, PhD, University of North Carolina at Chapel Hill
ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator. (Abstract 276) - Jolyn Sharpe Taylor, MD, The University of Texas MD Anderson Cancer Center
What is the real rate of surgical-site infection? (Abstract 171) - Melisa L. Wong, MD, University of California, San Francisco
Improving venous thromboembolism (VTE) prophylaxis for hospitalized malignant hematology/bone marrow transplant (heme/BMT) patients. (Abstract 79)
The 2016 Conquer Cancer Foundation of ASCO Merit Awards in Quality Care are supported by Amgen; AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Janssen Oncology; Lilly; Spectrum Pharmaceuticals; and Takeda Oncology.
Comments
Ruinuo Jia, MD
Mar, 15 2016 10:43 AM
Congratulations!